{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PCI-32765", "query": { "intervention": "PCI-32765" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 269, "total_pages": 27, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PCI-32765&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T14:24:26.420Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01752426", "title": "Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Heavy Water (2H2O)", "type": "OTHER" }, { "name": "PCI-32765", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2012-12-17", "completion_date": "2018-08-09", "has_results": true, "last_update_posted_date": "2020-02-24", "last_synced_at": "2026-09-05T14:24:26.420Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01752426" }, { "nct_id": "NCT03267186", "title": "Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Biphenotypic Leukemia", "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Hematopoietic Cell Transplantation Recipient" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Andrew Rezvani", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 8, "start_date": "2017-09-12", "completion_date": "2021-04-30", "has_results": true, "last_update_posted_date": "2023-08-01", "last_synced_at": "2026-09-05T14:24:26.420Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03267186" }, { "nct_id": "NCT06136559", "title": "A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Nemtabrutinib", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1200, "start_date": "2023-12-13", "completion_date": "2032-09-07", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-05T14:24:26.420Z", "location_count": 46, "location_summary": "Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 42 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Prescott", "state": "Arizona" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06136559" }, { "nct_id": "NCT03679624", "title": "Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Waldenstrom Macroglobulinemia", "Waldenstrom's Disease", "Waldenström; Hypergammaglobulinemia", "Waldenstrom's Macroglobulinemia Recurrent", "Waldenstrom's Macroglobulinemia of Lymph Nodes", "Waldenstrom's Macroglobulinaemia, Without Mention of Remission", "Waldenstrom's Macroglobulinemia Refractory" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2020-07-30", "completion_date": "2020-10-13", "has_results": true, "last_update_posted_date": "2023-10-23", "last_synced_at": "2026-09-05T14:24:26.420Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03679624" }, { "nct_id": "NCT04477291", "title": "A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "CG-806", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aptose Biosciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2020-10-06", "completion_date": "2024-04-15", "has_results": false, "last_update_posted_date": "2025-03-07", "last_synced_at": "2026-09-05T14:24:26.420Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • Miami, Florida + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04477291" }, { "nct_id": "NCT02129062", "title": "Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult B Acute Lymphoblastic Leukemia", "Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1", "Recurrent Adult Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2014-04", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-01-16", "last_synced_at": "2026-09-05T14:24:26.420Z", "location_count": 8, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02129062" }, { "nct_id": "NCT01479842", "title": "Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Splenic Marginal Zone Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "BTK inhibitor PCI-32765", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "bendamustine hydrochloride", "type": "DRUG" }, { "name": "pharmacogenomic studies", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Kami Maddocks, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2014-03-26", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-05T14:24:26.420Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01479842" }, { "nct_id": "NCT03310619", "title": "A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Follicular" ], "interventions": [ { "name": "JCAR017", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "CC-122", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "CC-220", "type": "DRUG" }, { "name": "Relatlimab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "CC-99282", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2017-12-20", "completion_date": "2023-02-15", "has_results": true, "last_update_posted_date": "2024-04-04", "last_synced_at": "2026-09-05T14:24:26.420Z", "location_count": 9, "location_summary": "Duarte, California • Atlanta, Georgia • Chicago, Illinois + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03310619" }, { "nct_id": "NCT01849263", "title": "Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Grade 3a Follicular Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Refractory Follicular Lymphoma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2013-04-02", "completion_date": "2027-03-19", "has_results": true, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-09-05T14:24:26.420Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Saint Louis Park", "state": "Minnesota" }, { "city": "Saint Louis Park", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01849263" }, { "nct_id": "NCT02604511", "title": "Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Waldenstrom's Macroglobulinemia" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2016-01", "completion_date": "2022-11-01", "has_results": true, "last_update_posted_date": "2022-12-07", "last_synced_at": "2026-09-05T14:24:26.420Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02604511" } ] }